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Abstract
Aims In hospitalized patients with a clinical diagnosis of acute heart failure (HF) with preserved ejection fraction (HFpEF), the
aims of this study were (i) to assess the proportion meeting the 2016 European Society of Cardiology (ESC) HFpEF criteria and
(ii) to compare patients with restrictive/pseudonormal mitral inflow pattern (MIP) vs. patients with MIP other than
restrictive/pseudonormal.
Methods and results We included hospitalized participants of the ESC-Heart Failure Association (HFA) EURObservational Re-
search Programme (EORP) HF Long-Term Registry who had echocardiogram with ejection fraction (EF) ≥ 50% during index hos-
pitalization. As no data on e’, E/e’ and left ventricular (LV) mass index were gathered in the registry, the 2016 ESC HFpEF
definition was modified as follows: elevated B-type natriuretic peptide (BNP) (≥100 pg/mL for acute HF) and/or N-terminal
pro-BNP (≥300 pg/mL) and at least one of the echocardiographic criteria: (i) presence of LV hypertrophy (yes/no), (ii) left atrial
volume index (LAVI) of >34 mL/m2), or (iii) restrictive/pseudonormal MIP. Next, all patients were divided into four groups: (i)
patients with restrictive/pseudonormal MIP on echocardiography [i.e. with presumably elevated left atrial (LA) pressure], (ii)
patients with MIP other than restrictive/pseudonormal (i.e. with presumably normal LA pressure), (iii) atrial fibrillation (AF)
group, and (iv) ‘grey area’ (no consistent description of MIP despite no report of AF). Of 6365 hospitalized patients, 1848
(29%) had EF ≥ 50%. Natriuretic peptides were assessed in 28%, LV hypertrophy in 92%, LAVI in 13%, and MIP in 67%. The
2016 ESC HFpEF criteria could be assessed in 27% of the 1848 patients and, if assessed, were met in 52%. Of the 1848 patients,
19% had restrictive/pseudonormal MIP, 43% had MIP other than restrictive/pseudonormal, 18% had AF and 20% were grey
area. There were no differences in long-term all-cause or cardiovascular mortality, or all-cause hospitalizations or HF
rehospitalizations between the four groups. Despite fewer non-cardiac comorbidities reported at baseline, patients with
MIP other than restrictive/pseudonormal (i.e. with presumably normal LA pressure) had more non-cardiovascular (14.0 vs.
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6.7 per 100 patient-years, P < 0.001) and cardiovascular non-HF (13.2 vs. 8.0 per 100 patient-years, P = 0.016) hospitalizations
in long-term follow-up than patients with restrictive/pseudonormal MIP.
Conclusions Acute HFpEF diagnosis could be assessed (based on the 2016 ESC criteria) in only a quarter of patients and con-
firmed in half of these. When assessed, only one in three patients had restrictive/pseudonormal MIP suggestive of elevated LA
pressure. Patients with MIP other than restrictive/pseudonormal (suggestive of normal LA pressure) could have been
misdiagnosed with acute HFpEF or had echocardiography performed after normalization of LA pressure. They were more often
hospitalized for non-HF reasons during follow-up. Symptoms suggestive of acute HFpEF may in some patients represent
non-HF comorbidities.
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Introduction
Compared with heart failure (HF) with reduced ejection frac-
tion (HFrEF), the diagnosis of HF with preserved EF (HFpEF)
remains challenging.1–4 HFpEF is accompanied by multiple
cardiovascular and non-cardiovascular comorbidities, poten-
tially confusing the HFpEF diagnosis, as some of them present
with symptoms that can mimic HF.5–9 A growing understand-
ing of the pathophysiology and clinical characteristics of
HFpEF has resulted in proposals to identify a distinct clinical
entity and attempts to develop specific diagnostic criteria.1–
4 Among these is the 2016 European Society of Cardiology
(ESC) definition.1
In the ESC EURObservational Research Programme (EORP)
HF Long-Term (LT) Registry, EF of >45% was significantly
more often reported in hospitalized compared with ambula-
tory HF patients (33% vs. 23%), suggesting that the diagnosis
of HFpEF is more readily made in the acute setting.10 A defi-
nite diagnosis of HFpEF requires echocardiographic assess-
ment of diastolic dysfunction and left atrial (LA) pressure,
which may frequently be neglected in clinical practice.4,11 Mi-
tral inflow patterns (MIPs) other than restrictive or
pseudonormal indicate normal LA pressures and thus pre-
clude left ventricular (LV) dysfunction as a leading cause of
symptoms in acutely ill patients.4,12–15
We hypothesized that, in clinical practice, a substantial
proportion of hospitalized patients with an EF of ≥50% and
acute symptoms suggestive of HF do not have
echocardiographic signs of increased LA pressure and thus,
might be potentially misdiagnosed as having acute HFpEF.
These patients might be burdened with comorbidities which
may, at least in part, account for their clinical presentation
and outcomes.
The aim was to assess the prevalence of HFpEF in hospital-
ized ESC-HF LT Registry participants with an EF of ≥50%, based
on (i) the 2016 ESC diagnostic criteria and (ii) echocardio-
graphic signs of elevated LA pressure, defined as restrictive
or pseudonormal MIP. Next, we sought to investigate
differences in baseline characteristics and long-term prognosis
of patients with and without restrictive/pseudonormal MIP.
Methods
Material and patient selection
The ESC HF LT Registry was a prospective, multicentre, obser-
vational study of HF patients, conducted by the EORP in 337
cardiology centres from 33 ESCMember countries (Supporting
Information, Appendix S1). The registry included adult HF pa-
tients (aged 18 years or more), both those hospitalized for
acute HF and ambulatory patients with chronic HF. There were
no specific exclusion criteria. Data on subsequent hospital ad-
missions and mortality were obtained at a mandatory
follow-up visit at 12months (if the patient was unable to reach
the clinical centre, the follow-up visit was replaced by a tele-
phone call). The registry was approved by local ethical review
boards according to the regulations of each participating coun-
try. All patients enrolled in the survey signed an informed con-
sent, unless exempt by the local ethics committee.16,17
The current analysis included patients hospitalized for
acute HF who had an echocardiogram with EF ≥ 50% during
the index hospitalization. Patients with acute HFrEF
(EF < 40% on echocardiogram performed during the index
hospitalization) and HF with mid-range EF (HFmrEF; EF 40–
49%) were included for outcome comparisons only.
Assessment of the 2016 European Society of
Cardiology criteria for heart failure with
preserved ejection fraction
We first assessed if the 2016 ESC criteria for HFpEF1 were
met: elevated concentrations of natriuretic peptides [for
acute HF: B-type natriuretic peptide (BNP) of ≥100 pg/mL
and/or N-terminal pro-BNP (NT-proBNP) of ≥300 pg/mL]
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and at least one of the echocardiographic criteria: (i) pres-
ence of LV hypertrophy (yes/no; no data on LV mass index
were collected in the registry), (ii) LA enlargement [left atrial
volume index (LAVI) of >34 mL/m2], or (iii) diastolic dysfunc-
tion [as no tissue Doppler imaging (TDI)-derived data (includ-
ing e’ and E/e’ ratio) were gathered in the registry, we used a
surrogate in the form of restrictive or pseudonormal MIP].
Comparison of patients with and without
restrictive/pseudonormal mitral inflow pattern
Next, we sought to identify and compare patients with
restrictive/pseudonormal MIP suggestive of elevated
LA pressure and patients with MIP other than
restrictive/pseudonormal whomight have had normal LA pres-
sures despite having been diagnosed with acute HFpEF. Given
the lack of some data in the registry [including e’, E/e’ ratio,
and tricuspid regurgitation velocity (TRV) unavailable in all pa-
tients, LAVI missing in 87%], we were unable to accurately fol-
low the algorithm for LA pressure estimation proposed by the
American Society of Echocardiography (ASE) and the European
Association of Cardiovascular Imaging (EACVI).4 Natriuretic
peptides concentrationsweremissing in 72%of patients. Thus,
we divided patients into four groups based onMIP on echocar-
diography performed during index hospitalization:
1 patients with restrictive/pseudonormal MIP suggestive of
elevated LA pressure (Table 1),
2 patients with MIP other than restrictive/pseudonormal,
suggestive of normal LA pressure (Table 1),
3 ‘atrial fibrillation (AF) group’—patients who most likely
had AF during echocardiographic evaluation, which made
it impossible to assess MIP (this included patients with
AF in electrocardiograms performed during index hospital-
ization and with no data on MIP on echocardiography),
4 ‘grey area’—patients with MIP assessed but impossible to
classify (as defined in Table 1) or with no data on MIP de-
spite no report of AF during index hospitalization.
We compared these four groups with regard to baseline
characteristics, course of index hospitalization (clinical status,
laboratory tests’ results, and implemented therapies), and
in-hospital and long-term outcomes.
For completeness, we also compared long-term prognosis
(all-cause death and all-cause death or HF rehospitalization)
of patients with EF ≥ 50% and restrictive/pseudonormal
MIP and patients with EF ≥ 50% and MIP other than
restrictive/pseudonormal with that of HFrEF and of HFmrEF
patients but performed no other analyses on HFrEF or
HFmrEF. The hypothesis behind that analysis was that pa-
tients with EF ≥ 50% and restrictive/pseudonormal MIP might
have prognosis more similar to that of ‘true’ HF (i.e. HFrEF or
HFmrEF), while patients with EF ≥ 50% and MIP other than
restrictive/pseudonormal might be at a lower risk of death
and HF events.
Statistical analysis
Categorical data were presented as percentages. Continu-
ous variables were reported as median and interquartile
range or as mean ± standard deviation as appropriate.
For categorical variables, among-group comparisons were
made using a χ2 test or a Fisher’s exact test. For continu-
ous variables, among-group comparisons were made using
a non-parametric test (Kruskal–Wallis test). Long-term out-
comes were presented as event rates per 100 patient-
years, and pairwise comparisons between groups were
made using Poisson regression model. Kaplan–Meier curves
were plotted for all-cause death and a composite of
all-cause death and HF rehospitalization and pairwise com-
parisons were performed between the groups. All tests
were two-sided. For all tests, a P value of less than 0.05
was deemed significant. All statistical analyses were con-
ducted using SAS statistical software version 9.4 (SAS Insti-
tute, Inc., Cary, NC, USA).
Table 1 Echocardiographic estimation of left atrial (LA) pressure based on mitral inflow pattern and data available in the ESC-HFA EORP
Heart Failure Long-Term Registry
Estimated LA pressure Mitral inflow pattern Data in the registrya
Presumably elevated restrictive or pseudonormal ● mitral inflow pattern described as restrictive/pseudonormal
(and E/A > 0.8, if E/A ratio available),
● or E/A ≥ 2 (if only E/A ratio given)
Presumably normal other than restrictive/pseudonormal
(normal or impaired relaxation)
● mitral inflow pattern described as other than
restrictive/pseudonormal (and E/A < 2, if E/A ratio available),
● or E/A ≤ 0.8 (if only E/A ratio given)
Impossible to classifyb impossible to classify or not assessed ● no description of mitral inflow pattern and no data on E/A ratio,
● or E/A between 0.8 and 2.0 (if only E/A ratio given)
● both description of mitral inflow pattern and E/A ratio
given, but their results - inconsistent
ESC, European Society of Cardiology; EORP, EURObservational Research Programme; HFA, Heart Failure Association.
aIn the registry, data on mitral inflow pattern were entered: (i) dichotomously as ‘restrictive/pseudonormal pattern’—yes vs. no, (ii) as E/A
ratio.
bIncluded in the ‘grey area’ group if no atrial fibrillation present.
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Results
Patients
A total of 19 135 patients were enrolled in the registry be-
tween March 2011 and May 2017, including 6365 hospital-
ized patients with EF assessed echocardiographically during
the index hospitalization. Out of these, 1848 patients (29%)
had an EF of ≥50%—these patients were included in further
analyses (flow-chart, Figure 1).
Prevalence of heart failure with preserved
ejection fraction based on the 2016 European
Society of Cardiology criteria
In 1848 patients with EF ≥50%, we displayed the extent to
which individual criteria were assessed, and if they were
assessed, to what extent criteria for HFpEF were met (Figure
2A), and the extent to which it was possible to assess the
2016 ESC HFpEF definition (in 27%), and if assessed, to what
extent the 2016 ESC HFpEF definition was met (in 52% of the
27% possible to assess) (Figure 2B).
Patient groups based on mitral inflow pattern
Out of 1848 patients, 19% had restrictive/pseudonormal MIP
indicative of elevated resting LA pressure, while 43% had
MIP other than restrictive/pseudonormal suggestive of
normal LA pressure (Figure 1). Clinical, laboratory, and
echocardiographic characteristics of the four groups (patients
with restrictive/pseudonormal MIP, patients with MIP other
than restrictive/pseudonormal, AF group and grey area
patients) are presented in Table 2.
Outcomes of patients with and without
restrictive/pseudonormal mitral inflow patterns
Median follow-up was 393 days (interquartile range: 366–
539 days). In-hospital and long-term outcomes of the four
groups are presented in Tables 3 and 4, and in Figure 3. There
were no significant differences between the four groups with
regard to in-hospital mortality, long-term all-cause and
cardiovascular mortality, as well as long-term all-cause
hospitalizations. However, notably, patients with MIP
other than restrictive/pseudonormal had a rate of
non-cardiovascular hospitalizations twice as high as patients
with restrictive/pseudonormal MIP. Furthermore, patients
with MIP other than restrictive/pseudonormal also had a
significantly higher rate of cardiovascular non-HF
hospitalizations in long-term follow-up than patients with
restrictive/pseudonormal MIP.
Kaplan–Meier curves for comparison of long-term
outcomes of patients with EF ≥ 50% and
restrictive/pseudonormal MIP, patients with EF ≥ 50% and
MIP other than restrictive/pseudonormal, HFmrEF and HFrEF
are shown in Figure 4. Pairwise comparisons of all-cause mor-
tality showed significantly lower survival (P < 0.001) in HFrEF
compared with all three remaining groups, with no statistically
significant differences between the three remaining groups.
Figure 1 Patient selection and distribution between groups. AF, atrial fibrillation; EF, ejection fraction; ESC, European Society of Cardiology; HF, heart
failure; HFpEF, heart failure with preserved ejection fraction; MIP, mitral inflow pattern; pts, patients; TTE, transthoracic echocardiogram.
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For the composite of all-cause death or rehospitalization for
HF, pairwise comparisons showed again significantly worse
outcomes (P < 0.001) in HFrEF vs. all three remaining
groups, as well as in patients with HFpEF and
restrictive/pseudonormal MIP compared with the HFmrEF
group (P = 0.01). There was a trend towards greater risk for
patients with HFpEF and restrictive/pseudonormal MIP vs.
patients with EF ≥ 50% and MIP other than
restrictive/pseudonormal (P = 0.08). There was no significant
difference between the HFmrEF group and patients with
EF ≥ 50% and MIP other than restrictive/pseudonormal.
Thus, in summary, among patients diagnosed with acute
HFpEF (EF ≥ 50%), those with restrictive/pseudonormal MIP
(suggestive of elevated LA pressure) vs. those with MIP other
than restrictive/pseudonormal (i.e. with presumably normal
LA pressure) had lower risk of non-cardiovascular and cardio-
vascular non-HF hospitalizations, and a trend towards higher
risk of death or HF rehospitalization in long-term follow-up.
Figure 2 Proportion of patients meeting the 2016 ESC criteria for heart failure with preserved ejection fraction: (A) patients meeting individual criteria,
(B) patients meeting the 2016 ESC definition. BNP, B-type natriuretic peptide; ESC, European Society of Cardiology; HFpEF, heart failure with preserved
ejection fraction; LAVI, left atrial volume index; NTproBNP, N-terminal proBNP; pts, patients.
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Discussion
In this large generalizable study of acute presumed HFpEF
(EF ≥ 50%), a diagnosis of HFpEF based on the 2016 ESC HF
guidelines could be assessed in only a quarter of patients,
and was confirmed in only half of these. Patients with HFpEF
and signs of elevated LA pressure on echocardiography had
lower risk of subsequent non-HF hospitalizations, and po-
tentially greater risk of death or HF rehospitalization.
Several different HFpEF definitions have been proposed,
from a symptom-based, in part ‘diagnosis of exclusion’ ap-
proach in early randomized clinical trials, to
biomarker-orientated and echocardiography-orientated di-
agnostic criteria in recent trials and guidelines.1–4,18–23 The
latter put particular emphasis on the presence of objective
evidence of structural and/or functional disease. The most
recent Heart Failure Association (HFA)-Pre-test assessment,
Echocardiography & natriuretic peptide, Functional testing,
Final aetiology (PEFF) score includes a number of variables
(grouped within the functional, morphological, and bio-
marker domain) to be assessed when diagnosing HFpEF.3 Al-
though natriuretic peptides carry undeniable importance in
the diagnostic and prognostic evaluation of HF, their speci-
ficity may be limited in elderly patients with multiple comor-
bidities (such as AF, renal failure, frailty/cachexia, or
respiratory diseases)—which represents a common clinical
setting in HFpEF.7 The 2016 guideline-recommended upper
limits of natriuretic peptides’ concentrations constitute ex-
clusionary cut-off points, and should be used for ruling-
out, rather than ruling in, a HF diagnosis.1 The HFA-PEFF
score, on the other hand, introduced different cut-offs for
natriuretic peptides, depending on the presence or absence
of AF (with cut-points in AF three times higher than in sinus
rhythm), as well as on criterion type (major vs minor).3 Im-
portantly, the HFA-PEFF score is dedicated for diagnosing
chronic HFpEF.3 In our study, natriuretic peptides were ele-
vated in all four analysed groups (i.e. HF could not be ‘ruled
out’), with the highest NT-proBNP concentrations in pa-
tients with restrictive/pseudonormal MIP and the ‘AF
group’. Increased natriuretic peptides in patients with MIP
other than restrictive/pseudonormal (suggestive of normal
LA pressure) and the grey area groupmight be explained pri-
marily by the fact that they were measured at presentation
whereas echocardiography may have been delayed allowing
clinical improvement, or by old age, presence of chronic kid-
ney disease in approximately one quarter, chronic obstruc-
tive pulmonary disease in one fifth and uncontrolled
hypertension in one quarter of those patients, and presence
of AF at hospital admission in one third of patients
with MIP subsequently described as other than
restrictive/pseudonormal.
Pulmonary congestion is secondary to an increase in LV
filling pressures, and thus, in a decompensated HF patient,
at least with acute dyspnoea, evidence for elevated LATa
b
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pressure is to be expected on resting echocardiography, un-
less echocardiography is obtained after haemodynamics have
improved with treatment. Lack of echocardiographic signs of
elevated LA pressure should alert to other possible causes of
acute dyspnoea. Echocardiographic estimation has proven a
reliable tool to identify patients with elevated LA pressure,
as verified by invasive measurements.12–14 A full echocardio-
graphic assessment of diastolic function and LV filling pres-
sures involves a complex diagnostic algorithm with a central
role of TDI-derived measurements (e’, E/e’) in recognizing
Table 4 Long-term outcomes of the four groups of patients with preserved ejection fraction
Variable
Hospitalized patients with EF ≥ 50%
Pa
MIP restrictive/
pseudonormal
MIP other
than restrictive/
pseudonormal AF group Grey area group
Lost to follow-up 2.2% 8/356 9.2% 73/797 7.1% 23/324 9.2% 34/371 0.001
All-cause death 19.5% 66/339 18.0% 126/699 22.3% 64/287 18.9% 61/322 0.49
Cardiovascular death 11.5% 39/339 8.6% 60/699 11.5% 33/287 10.9% 35/322 0.35
Non-cardiovascular death 2.4% 8/339 3.9% 27/699 5.6% 16/287 4.3% 14/322 0.22
Unknown cause of death 5.6% 19/339 5.6% 39/699 5.2% 15/287 3.7% 12/322 0.63
All-cause hospitalization 34.8% 118/339 40.1% 280/699 38.7% 111/287 38.8% 125/322 0.44
Cardiovascular (non-HF)
hospitalization
9.1% 31/339 14.4% 101/699 15.7% 45/287 13.7% 44/322 0.06
Rehospitalization for HF 20.4% 69/339 16.3% 114/699 17.4% 50/287 15.8% 51/322 0.37
Non-cardiovascular hospitalization 7.7% 26/339 16.3% 114/699 11.1% 32/287 14.0% 45/322 0.001
All-cause death or rehospitalization for HF 32.4% 110/339 29.3% 205/699 36.2% 104/287 30.1% 97/322 0.18
AF, atrial fibrillation; EF, ejection fraction; HFpEF, heart failure with preserved ejection fraction; MIP, mitral inflow pattern.
aP - for comparison between the four groups.
Bolded font indicates p values of <0.1.
Table 3 Clinical course of index hospitalization, implemented therapies and in-hospital outcomes of the four groups of patients with pre-
served ejection fraction
Variable
Hospitalized patients with EF ≥ 50% (n = 1848)
Pa
MIP restrictive/
pseudonormal
n = 356
MIP other than restrictive/
pseudonormal
n = 797
AF group
n = 324
Grey area group
n = 371
In-hospital management and outcomes
Nitrates during hospitalization 43% 27% 19% 24% <0.001
Diuretics during hospitalization 83% 82% 81% 72% <0.001
Coronary angiography
during hospitalization
17% 19% 11% 23% <0.001
PCI/CABG during hospitalization 7.0% 9.4% 2.8% 9.0% 0.003
Hospitalization length (days) 7 (4–12) 7 (5–11) 7 (5–12) 7 (4–13) 0.74
Death during hospitalization 2.5% 9/356 3.1% 25/797 4.3% 14/324 4.0% 15/371 0.51
Clinical status at dischargeb
Heart rate (b.p.m.) 68 (60–75) 70 (63–80) 74 (66–85) 70 (64–78) <0.001
SBP (mm Hg) 120 (110–130) 120 (110–133) 120 (110–130) 120 (110–140) 0.06
NYHA class
NYHA I/II 89% 82% 74% 77% <0.001
NYHA III 8.7% 17% 24% 20% <0.001
NYHA IV 2.0% 1.4% 2.2% 3.0% 0.39
Pharmacotherapy at hospital discharge
Loop and/or thiazide diuretic 69% 78% 85% 76% <0.001
Daily dose of loop diuretic
(equivalent to furosemide dose)c
76 (±113) n = 219 62 (±88) n = 560 59 (±105) n = 225 54 (±53)
n = 234
0.02
Aldosterone antagonist 35% 30% 47% 34% <0.001
ACE-I or ARB 79% 72% 66% 72% 0.001
β-blocker 71% 70% 72% 67% 0.57
Calcium channel blocker 19% 27% 21% 23% 0.005
ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CABG, coronary artery bypass
grafting; EF, ejection fraction; HFpEF, heart failure with preserved ejection fraction; NYHA, New York Heart Association PCI, percutaneous
coronary intervention; SBP, systolic blood pressure.
aP - for comparison between the four groups.
bIn those who survived to hospital discharge.
cOne milligram bumetanide = 20 mg torsemide = 40 mg furosemide.
Bolded font indicates p values of <0.5.
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diastolic dysfunction; however, the final distinction between
elevated and normal LA pressure and grading of diastolic dys-
function are largely based on MIP, with E/A ≥ 2 (consistent
with ‘restrictive’ MIP) indicative of significantly increased LA
pressure and grade III diastolic dysfunction, and E/A ≤ 0.8 in-
dicative of normal LA pressure.4 Patients with E/A ratio be-
tween 0.8 and 2 should be further assessed to discriminate
between ‘normal’ and ‘pseudonormal’ (i.e. indicative of ele-
vated LA pressure and grade II diastolic dysfunction) MIP. Al-
though neither TDI-derived parameters nor TRV were
gathered in the registry database, it is reasonable to assume
that some investigators must have had access to those data
allowing them to discriminate between patients with
pseudonormal (classified as ‘restrictive/pseudonormal’ in
the registry database) and normal (classified as ‘other than
restrictive/pseudonormal’) MIP. Out of 1239 patients with
MIP assessed, 1157 (93%) were allocated to the
restrictive/pseudonormal or the ‘other’ MIP group by the in-
vestigators (possibly based also on echocardiographic param-
eters other than E/A ratio), and classification of MIP based
merely on E/A ratio was performed only in the remaining 7%.
We included patients hospitalized for presumed acute HF,
but MIP was restrictive/pseudonormal (indicative of
elevated LA pressure) in only 29% of those with MIP assessed
(19% of the whole HFpEF group) and other than
restrictive/pseudonormal (indicative of normal LA pressure)
in 64% of those with MIP assessed (43% of the whole group),
suggesting that among the latter, acute HF presentation
could potentially be attributable to reasons other than HF
and that even if those patients indeed had chronic HFpEF, it
may not have been the main reason for the present symptom
exacerbation. However, contrary to our initial hypothesis,
patients with MIP other than restrictive/pseudonormal (who
potentially might have been misdiagnosed with HFpEF) were
Figure 3 Long-term outcomes: event rates in the four groups of patients with preserved ejection fraction. For pairwise comparisons between groups,
only P values of <0.1 are given (with P values of <0.05 marked in red). AF, atrial fibrillation; HF, heart failure; MIP, mitral inflow pattern.
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characterized by fewer concomitant cardiac and non-cardiac
comorbidities than patients with restrictive/pseudonormal
MIP. A high prevalence of comorbidities is expected in
HFpEF,1,8,24,25 but we expected it to be even higher in pa-
tients potentially misdiagnosed with HFpEF. Nevertheless, in
long-term follow-up, despite fewer non-cardiac comorbidities
reported at baseline, patients with MIP other than
restrictive/pseudonormal (i.e. potentially misdiagnosed with
HFpEF) had twice as many non-cardiovascular hospitalizations
as patients with restrictive/pseudonormal MIP, which is more
consistent with non-HF causes of frailty and symptoms mis-
taken for HF and a pattern previously described,26 and might
indicate that at least some of those patients did have some
relevant comorbidities that had not yet been recognized at
the time of the index hospitalization. This underlines the need
for careful assessment of elderly patients presenting with
dyspnoea, impaired exercise tolerance, or oedema, for
hitherto unknown comorbidities that could either imitate or
exacerbate HF symptoms.
Conversely, in long-term follow-up, patients with
restrictive/pseudonormal MIP tended to experience the
composite endpoint of death or HF rehospitalization more
often, although the difference did not reach statistical
significance. Moreover, patients with EF ≥ 50% and
restrictive/pseudonormal MIP had a significantly higher risk
for all-cause death or HF rehospitalization than HFmrEF
patients, which might be regarded as a ‘post-factum’
validation of their initial HF diagnosis. Compared with
patients with MIP suggestive of normal LA pressure, patients
with restrictive/pseudonormal MIP had more severe HF
symptoms at hospital admission (with higher heart rate,
higher New York Heart Association class and more pulmonary
congestion), and on echocardiography—larger LAVI and
higher prevalence of moderate-to-severe mitral and
Figure 4 Kaplan–Meier curves for patients with preserved, mid-range and reduced ejection fraction: (A) all-cause death, (B) all-cause death or rehos-
pitalization for heart failure. HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFrEF, heart failure with reduced ejection frac-
tion; MIP, mitral inflow pattern; r/p, restrictive/pseudonormal.
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tricuspid regurgitation. Despite the same frequency of
diuretic therapy during hospitalization, patients with
restrictive/pseudonormal MIP experienced more significant
improvement in HF symptoms than patients with other MIP
—possibly because they were correctly diagnosed and ade-
quately treated. Indeed, the sole 2016 ESC recommendation
on HFpEF treatment concerns diuretic therapy to alleviate
symptoms.1 Taken together, these findings suggest that
echocardiographically assessed elevation of resting LA pres-
sure may not suffice to diagnose HFpEF but can identify pa-
tients with more severe HF and with greater risk of HF events.
Elevated LA pressure, estimated echocardiographically, has
been previously linked to unfavourable outcomes in HF.27–31
However, echocardiographic indices of diastolic dysfunction
and elevated LA pressure might not directly translate into re-
duced survival in HFpEF, partly because of their poor correla-
tion with factual LV filling pressures, but also because HFpEF
pathophysiology seems to be related not only to diastolic but
also preclinical systolic dysfunction.32–35
In our study, we analysed patients with AF during echocar-
diography as a separate group. Importantly, approximately
one third of patients in both restrictive/pseudonormal MIP
and other MIP group had AF at hospital admission but con-
verted to sinus rhythm by the time of echocardiographic eval-
uation (which enabled assessment of MIP). Atrial fibrillation
may be regarded as a confounder in HFpEF, first, because it
can lead to HF symptoms and elevation in natriuretic pep-
tides even in patients without HF, and second, because it hin-
ders echocardiographic assessment of diastolic function. On
the other hand, AF has the same risk factors as HFpEF and
is highly prevalent in HFpEF; in the ESC-HF LT Registry, AF
was present in 39% of HFpEF patients, and in 27% of HFrEF
patients,17 and in the less selective Swedish Heart Failure
Registry, AF was present in 65% in HFpEF, 60% in HFmrEF,
and 53% in HFrEF.36 Furthermore, AF may be an important
exacerbating factor in chronic HF, as well as a cause of
tachycardia-induced cardiomyopathy. In HFpEF, AF was re-
lated to worse cardiovascular and all-cause outcomes.17,36
In our study, crude rates of all-cause and cardiovascular mor-
tality, as well as all-cause hospitalizations were similar for all
four analysed groups.
Interestingly, 73% of patients with preserved EF and acute
symptoms requiring hospitalization did not have their HF di-
agnosis verified during the index hospitalization, with a vast
majority lacking even a simple measurement of natriuretic
peptides. Naturally, this might result from the fact that ap-
proximately 30% were diagnosed with HFpEF previously.
Many of those patients might indeed have chronic HFpEF;
however, this does not necessarily mean that HF was respon-
sible for their current decompensation. In fact, once ‘labelled’
with an HF diagnosis, those patients were potentially more
likely to have their subsequent symptoms automatically at-
tributed to HF. Furthermore, some previous data suggest that
in everyday clinical practice, HF may be overdiagnosed in 16–
46% of patients.11,26,37,38 In our study, half of patients in
whom the 2016 ESC definition was assessed did not meet
those relatively ‘mild’ diagnostic criteria for HFpEF (elevated
natriuretic peptides, and at least one of the three: presence
of LV hypertrophy, enlarged LA, or diastolic dysfunction). Al-
most half of the 92% of patients in whom LV hypertrophy
was assessed had normal LV wall thickness, which is striking,
given that hypertensive LV hypertrophy in the elderly is the
most common cause of diastolic dysfunction and HFpEF. Fi-
nally, 43% of the whole group had MIP other than
restrictive/pseudonormal, suggesting normal LA pressure, de-
spite acute symptom exacerbation.
The lack of a single, universal HFpEF definition, as well as
the fact that no treatment has yet been shown to improve
survival in HFpEF, implies that we still fail to properly define
and diagnose HFpEF. The results of our study, on one hand,
show that securing acute HFpEF diagnosis with objective evi-
dence from biomarker measurements and echocardiography
may often be neglected in clinical practice but, on the other
hand, might reflect limitations of the tested definition itself.
A good HFpEF definition should facilitate estimation of risk
of future HF events and might originate from on-going or
forthcoming clinical trials, especially if they yield positive re-
sults in terms of HFpEF therapy. For now, the HFA-PEFF step-
wise approach, integrating functional, morphological, and
biomarker assessment, with evaluation both at rest and, in
cases of uncertainty, during exercise, might prove the most
reliable of different HFpEF diagnostic criteria.3
Limitations of the study
The limitations of our study arise mainly from the type of data
(i.e. registry-based). We had access only to MIP for LA pres-
sure estimation (and, consequently, for assessment of LV dia-
stolic dysfunction), as neither TDI-derived parameters (e’,
E/e’) nor TRV were collected in the registry. Applying MIP as
a sole indicator of LA pressure does not well distinguish be-
tween patients with elevated and normal LA pressure. How-
ever, no single echocardiographic parameter is fully accurate
in LA pressure estimation, and even E/e’ ratio shows relatively
poor correlation with pressures measured in invasive hemo-
dynamic studies.33,39,40 Thus, according to both the
ASE/EACVI guidelines4 and the HFA-PEFF algorithm,3 the diag-
nosis of diastolic dysfunction does not rely on a single echo-
cardiographic parameter but involves a complex algorithm.
According to the ASE/EACVI guidelines, while E/e’ ratio (to-
gether with e’, LAVI and TRV) is used for the diagnosis of dia-
stolic dysfunction in patients with normal EF, MIP (E/A) is the
major parameter used for its grading and LA pressure
estimation.4 A number of factors may influence MIP, including
severe valvular disease (especially severe mitral regurgita-
tion), right ventricular dysfunction, pericardial diseases, ar-
rhythmias, and conductance disturbances. We have not
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excluded such patients from our study (partly because it was
impossible to identify all of the potential confounders, for ex-
ample, no data on right ventricular function, pericardial dis-
eases, or atrioventricular block were gathered in the
Registry; based on data collected in the Registry, it was impos-
sible to discriminate between severe and moderate valvular
disease). Instead, we have distinguished the AF group and
the grey area group, which included patients in whom MIP
was either not assessed or could not have been assessed
due to potential confounders. Despite its limitations, MIP
has proven useful in clinical practice, for example, for differen-
tial diagnosis of acute dyspnoea, as well as for guiding diuretic
therapy or optimizing LV assist devices settings in HF
patients.12,14,41 Pseudonormal or restrictive MIP has also been
shown to predict poor prognosis in HF patients.29–31 Although
data from right heart catheterization were gathered in the
registry, the study was performed only in 1.6% patients and
thus could not be used for LA pressure classification in our
analysis. Information on LV hypertrophy was reported at the
discretion of investigators as either ‘yes’ or ‘no’, with no data
on LV mass index gathered in the survey. Furthermore, a large
portion of data on LAVI and natriuretic peptides was missing.
Thus, the actual number of patients fulfilling the 2016 ESC
HFpEF criteria1 or the 2016 echocardiographic definition of di-
astolic dysfunction4 was impossible to determine. Further-
more, the 2016 ESC HFpEF definition applied in this analysis
may be considered a combination of acute (natriuretic pep-
tides) and chronic HF criteria (e.g. a cut-off for LAVI in acute
HFpEF might be higher due to hypervolemia). Next, no infor-
mation on the exact time point of echocardiographic evalua-
tion was given in the registry, and it is possible that in a
substantial portion of patients with LA pressure elevated on
hospital admission, it normalized with diuretic treatment by
the time of echocardiographic examination and MIP assess-
ment. Still, restrictive/pseudonormal MIP at the time of echo-
cardiographic evaluation indicative of elevated LA pressure
persisting after several days of treatment might reflect a more
advanced disease. In a study by Okura et al., in patients with
congestive HFpEF and LA pressure estimated on echocardiog-
raphy, LA pressure elevated after medical therapy indepen-
dently predicted death or unplanned HF hospitalization,
while initially elevated LA pressure did not.32 Furthermore,
in patients with no orthopnoea/resting dyspnoea, echocardi-
ography at rest may show normal LA pressure even in the
presence of HFpEF; thus, some patients with MIP other than
restrictive/pseudonormal might, in fact, have had HFpEF. In
some patients, the diagnosis of HFpEF might have been made
before the index hospitalization. Also, there was no informa-
tion on the actual heart rhythm during the echocardiographic
study, and allocation to the AF group was based on the pres-
ence of AF on the available electrocardiograms and a lack of
MIP assessment on echocardiography. However, we created
the AF group primarily to assess the proportion of patients
in whom lack of data on MIP might have been ‘justified’.
Causes of subsequent re-hospitalizations were allocated by in-
vestigators based on their clinical judgement, and thus, HF
rehospitalizations might have potentially been misclassified.
Finally, a small proportion of patients (7.5%) were lost to
follow-up: significantly fewer patients were lost to follow-up
in the restrictive/pseudonormal MIP group (2.2%, P < 0.001)
compared with the remaining three groups (9.2%, 7.1% and
9.2% in the other MIP, ‘AF’ and grey area group, respectively).
Conclusions
In clinical practice, a diagnosis of acute HFpEF appears to be
made clinically rather than by natriuretic peptides and echo-
cardiography. Assessment of the 2016 ESC HFpEF criteria
was possible only in a quarter of hospitalized patients with
preserved EF, and in this quarter, only half met the 2016
ESC criteria for HFpEF. In patients hospitalized for presumed
acute HFpEF in whom MIP was assessed, less than one third
had echocardiographic signs of elevation of estimated LA
pressure (restrictive/pseudonormal MIP), and two thirds
had presumably normal LA pressure (MIP other than
restrictive/pseudonormal). This might be explained by acute
HFpEF misdiagnosis, but also by echocardiography having
been performed after clinical stabilization and normalization
of filling pressures, or by AF that subsequently converted to
sinus rhythm. Despite fewer non-cardiac comorbidities
reported at baseline, patients with presumably normal LA
pressure (MIP other than restrictive/pseudonormal) had
higher risk for subsequent non-cardiovascular and
cardiovascular non-HF hospitalizations, while those with
restrictive/pseudonormal MIP (suggestive of elevated LA
pressure) had a trend towards higher risk of death or HF re-
hospitalization in long-term follow-up. This underscores the
need for accurate and objective verification of clinical HF diag-
nosis and careful screening for comorbidities in patients with
preserved EF presenting with symptoms suggestive of HF.
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